3M. E. LACOUTURE, M. L.MAITLAND, S. SEGAERT, et al.A proposed EGFR inhibitor dermatologic adverse event- specific grading scale from the MASCC skin toxicity study group[J].Supportive Care in Cancer,2010, 18(4) :509-522.
4Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002,346(2) :92 -98.
5Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo- naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J]. Ann Oncol, 2013,24( 1 ) : 54 - 59.
6Serizawa M, Koh Y, Kenmotsu H, et al. Assessment of mu- tational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study [J]. Cancer, 2014,120(10) :1471 - 1481.
7Schneider CP, Heigener D, Schott-von-Romer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study [ J]. J Thorac Oncol, 2008,3 ( 12 ) : 1446 - 1453.
8Cohen MH, Williams GA, Sridhara R, et al. FDA Drug Ap-proval Summary : Gefitinib (ZD1839) (Iressa.()) Tablets [J]. Oncologist, 2003, 8(4) : 303 -306.
